| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Diseases | 9 | 2020 | 467 | 1.590 |
Why?
|
| Urethral Obstruction | 8 | 2023 | 56 | 1.480 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 4 | 2011 | 16 | 1.080 |
Why?
|
| Kidney | 16 | 2022 | 1321 | 1.080 |
Why?
|
| Glomerulonephritis | 6 | 2019 | 76 | 1.050 |
Why?
|
| Fetal Diseases | 9 | 2023 | 442 | 1.040 |
Why?
|
| Nephrology | 2 | 2024 | 143 | 0.960 |
Why?
|
| Kidney Failure, Chronic | 6 | 2023 | 856 | 0.950 |
Why?
|
| Urinary Bladder Neck Obstruction | 4 | 2018 | 28 | 0.950 |
Why?
|
| Hypertension | 11 | 2021 | 1262 | 0.910 |
Why?
|
| Interleukin-12 | 6 | 2009 | 118 | 0.810 |
Why?
|
| Receptors, Complement | 4 | 2009 | 35 | 0.760 |
Why?
|
| Kidney Transplantation | 4 | 2011 | 621 | 0.730 |
Why?
|
| Urinary Tract | 3 | 2020 | 60 | 0.710 |
Why?
|
| Renal Insufficiency | 3 | 2017 | 231 | 0.650 |
Why?
|
| Receptors, Immunologic | 2 | 2014 | 110 | 0.640 |
Why?
|
| Hypertension, Renal | 3 | 2018 | 36 | 0.640 |
Why?
|
| Lupus Nephritis | 2 | 2009 | 45 | 0.610 |
Why?
|
| Denys-Drash Syndrome | 1 | 2017 | 4 | 0.590 |
Why?
|
| WT1 Proteins | 1 | 2017 | 26 | 0.580 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2021 | 681 | 0.570 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2017 | 36 | 0.570 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2020 | 3066 | 0.560 |
Why?
|
| Chromosome Mapping | 5 | 2018 | 1068 | 0.550 |
Why?
|
| Urogenital Abnormalities | 2 | 2016 | 167 | 0.550 |
Why?
|
| Mice, Inbred MRL lpr | 4 | 2009 | 16 | 0.540 |
Why?
|
| Proteome | 2 | 2009 | 233 | 0.530 |
Why?
|
| Rats, Inbred SHR | 10 | 2020 | 64 | 0.510 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 30 | 0.510 |
Why?
|
| Proteomics | 2 | 2009 | 473 | 0.470 |
Why?
|
| Graft Survival | 3 | 2011 | 520 | 0.450 |
Why?
|
| Nephritis, Hereditary | 2 | 2022 | 21 | 0.410 |
Why?
|
| Genetic Variation | 3 | 2020 | 1470 | 0.400 |
Why?
|
| Receptor, Anaphylatoxin C5a | 4 | 2007 | 12 | 0.390 |
Why?
|
| Renal Replacement Therapy | 3 | 2018 | 139 | 0.390 |
Why?
|
| Monocytes | 4 | 2001 | 356 | 0.370 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2020 | 469 | 0.370 |
Why?
|
| Stroke | 5 | 2020 | 945 | 0.350 |
Why?
|
| Dendritic Cells | 6 | 2009 | 404 | 0.350 |
Why?
|
| Hemodiafiltration | 2 | 2021 | 17 | 0.340 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2009 | 8 | 0.340 |
Why?
|
| Humans | 61 | 2024 | 121122 | 0.340 |
Why?
|
| Kidney Tubules | 2 | 2013 | 84 | 0.340 |
Why?
|
| Ultrasonography, Prenatal | 7 | 2023 | 901 | 0.330 |
Why?
|
| Mutation | 4 | 2022 | 5737 | 0.320 |
Why?
|
| Female | 40 | 2023 | 64043 | 0.320 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2008 | 5 | 0.320 |
Why?
|
| Kidney Glomerulus | 4 | 2013 | 85 | 0.320 |
Why?
|
| Albuminuria | 3 | 2014 | 90 | 0.320 |
Why?
|
| Complement C3a | 2 | 2007 | 20 | 0.320 |
Why?
|
| Proteinuria | 2 | 2006 | 108 | 0.320 |
Why?
|
| Renal Dialysis | 4 | 2023 | 834 | 0.310 |
Why?
|
| Sulfhydryl Compounds | 1 | 2008 | 53 | 0.310 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2008 | 67 | 0.310 |
Why?
|
| Fetus | 3 | 2023 | 578 | 0.310 |
Why?
|
| Urinary Bladder | 4 | 2023 | 242 | 0.310 |
Why?
|
| Signal Transduction | 3 | 2014 | 4499 | 0.300 |
Why?
|
| Urologic Diseases | 2 | 2019 | 44 | 0.300 |
Why?
|
| Prenatal Care | 2 | 2023 | 289 | 0.290 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 2577 | 0.290 |
Why?
|
| Haplotypes | 5 | 2019 | 509 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 3 | 2021 | 470 | 0.290 |
Why?
|
| Complement Factor H | 2 | 2008 | 18 | 0.290 |
Why?
|
| Graft Rejection | 1 | 2011 | 577 | 0.290 |
Why?
|
| Complement C4 | 1 | 2007 | 5 | 0.280 |
Why?
|
| Plasma Exchange | 2 | 2018 | 83 | 0.280 |
Why?
|
| Histocompatibility Antigens | 1 | 2007 | 19 | 0.280 |
Why?
|
| Animals | 25 | 2021 | 33423 | 0.280 |
Why?
|
| Immunosuppressive Agents | 3 | 2014 | 645 | 0.280 |
Why?
|
| Retrospective Studies | 18 | 2023 | 15593 | 0.270 |
Why?
|
| Kidney Tubules, Proximal | 2 | 2004 | 110 | 0.270 |
Why?
|
| Infant | 16 | 2023 | 12219 | 0.260 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2019 | 48 | 0.260 |
Why?
|
| Genome-Wide Association Study | 2 | 2014 | 1632 | 0.260 |
Why?
|
| Mycophenolic Acid | 2 | 2016 | 50 | 0.260 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2018 | 16 | 0.260 |
Why?
|
| Rats | 7 | 2020 | 3645 | 0.250 |
Why?
|
| Cholera Toxin | 2 | 2009 | 43 | 0.250 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 214 | 0.240 |
Why?
|
| Animals, Congenic | 3 | 2020 | 6 | 0.240 |
Why?
|
| Male | 29 | 2022 | 58941 | 0.240 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2007 | 169 | 0.240 |
Why?
|
| Pregnancy | 10 | 2023 | 6854 | 0.240 |
Why?
|
| Protein Methyltransferases | 1 | 2004 | 9 | 0.230 |
Why?
|
| Child | 21 | 2024 | 23984 | 0.230 |
Why?
|
| Glomerular Mesangium | 3 | 2003 | 19 | 0.230 |
Why?
|
| Time Factors | 7 | 2017 | 5976 | 0.220 |
Why?
|
| Reperfusion Injury | 1 | 2004 | 103 | 0.220 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2018 | 12 | 0.210 |
Why?
|
| Risk Factors | 8 | 2021 | 9617 | 0.210 |
Why?
|
| Gene Expression Profiling | 3 | 2008 | 1673 | 0.210 |
Why?
|
| Disease Progression | 5 | 2018 | 1968 | 0.210 |
Why?
|
| Creatinine | 2 | 2021 | 376 | 0.210 |
Why?
|
| Mice | 13 | 2012 | 17406 | 0.210 |
Why?
|
| Cystoscopy | 3 | 2017 | 43 | 0.200 |
Why?
|
| Hematuria | 1 | 2022 | 49 | 0.200 |
Why?
|
| Biomarkers | 2 | 2018 | 2917 | 0.200 |
Why?
|
| Transplantation, Homologous | 3 | 2011 | 655 | 0.200 |
Why?
|
| Blood Pressure | 4 | 2016 | 1310 | 0.190 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2001 | 7 | 0.190 |
Why?
|
| Receptors, Peptide | 1 | 2001 | 48 | 0.190 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2001 | 27 | 0.190 |
Why?
|
| Consensus | 1 | 2024 | 602 | 0.190 |
Why?
|
| Cells, Cultured | 7 | 2020 | 3067 | 0.180 |
Why?
|
| Child, Preschool | 13 | 2021 | 13733 | 0.180 |
Why?
|
| Stromal Interaction Molecule 1 | 1 | 2020 | 7 | 0.180 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2000 | 8 | 0.180 |
Why?
|
| ORAI1 Protein | 1 | 2020 | 4 | 0.180 |
Why?
|
| Autoantibodies | 2 | 2020 | 421 | 0.180 |
Why?
|
| Crosses, Genetic | 2 | 2013 | 160 | 0.180 |
Why?
|
| Antigens, CD | 2 | 2000 | 424 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 5 | 2012 | 4327 | 0.170 |
Why?
|
| Lymphocytes | 2 | 2014 | 417 | 0.170 |
Why?
|
| Mice, Knockout | 5 | 2012 | 3760 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2011 | 974 | 0.170 |
Why?
|
| Perinatal Mortality | 2 | 2019 | 34 | 0.170 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2019 | 40 | 0.170 |
Why?
|
| Disease Models, Animal | 7 | 2020 | 4246 | 0.170 |
Why?
|
| Foreign-Body Migration | 2 | 2018 | 72 | 0.170 |
Why?
|
| RNA, Messenger | 6 | 2004 | 2826 | 0.160 |
Why?
|
| Prednisone | 1 | 1999 | 272 | 0.160 |
Why?
|
| Receptors, Interleukin | 1 | 1999 | 32 | 0.160 |
Why?
|
| Nephrosis, Lipoid | 1 | 2018 | 10 | 0.160 |
Why?
|
| Prognosis | 6 | 2018 | 4473 | 0.160 |
Why?
|
| Complement C5a | 3 | 2007 | 25 | 0.160 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2018 | 26 | 0.160 |
Why?
|
| Quantitative Trait Loci | 3 | 2018 | 266 | 0.160 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 471 | 0.160 |
Why?
|
| Hypertension, Renovascular | 1 | 2018 | 24 | 0.150 |
Why?
|
| Nervous System Malformations | 1 | 2020 | 126 | 0.150 |
Why?
|
| Germ Cells | 1 | 2019 | 193 | 0.150 |
Why?
|
| Complement C3 | 2 | 2013 | 49 | 0.150 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 244 | 0.150 |
Why?
|
| Infant, Newborn | 8 | 2020 | 7975 | 0.150 |
Why?
|
| Recurrence | 3 | 2011 | 1381 | 0.150 |
Why?
|
| Receptors, Fc | 1 | 2018 | 28 | 0.150 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2018 | 27 | 0.150 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 54 | 0.150 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 57 | 0.150 |
Why?
|
| Chromosomes, Mammalian | 1 | 2018 | 42 | 0.150 |
Why?
|
| Renal Artery Obstruction | 1 | 2018 | 33 | 0.150 |
Why?
|
| Nephritis | 1 | 2018 | 20 | 0.150 |
Why?
|
| Edema | 1 | 2019 | 134 | 0.150 |
Why?
|
| Mitochondrial Diseases | 1 | 2019 | 133 | 0.150 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 689 | 0.150 |
Why?
|
| Ammonia | 1 | 1998 | 68 | 0.150 |
Why?
|
| Anesthesia, General | 1 | 2018 | 110 | 0.150 |
Why?
|
| Survival Analysis | 4 | 2018 | 1454 | 0.150 |
Why?
|
| Citric Acid | 1 | 2017 | 35 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2001 | 748 | 0.140 |
Why?
|
| Catheters, Indwelling | 1 | 2018 | 156 | 0.140 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 62 | 0.140 |
Why?
|
| Lung | 3 | 2015 | 1461 | 0.140 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 1708 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 1999 | 375 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1524 | 0.140 |
Why?
|
| Peritoneal Dialysis | 1 | 2018 | 117 | 0.140 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 1870 | 0.140 |
Why?
|
| Hematocrit | 2 | 2014 | 110 | 0.140 |
Why?
|
| Forecasting | 1 | 2018 | 349 | 0.140 |
Why?
|
| Fetal Therapies | 1 | 2017 | 72 | 0.130 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 1996 | 15 | 0.130 |
Why?
|
| Liver Failure, Acute | 1 | 2017 | 88 | 0.130 |
Why?
|
| Coatomer Protein | 1 | 2016 | 30 | 0.130 |
Why?
|
| Nephrotic Syndrome | 1 | 1996 | 46 | 0.130 |
Why?
|
| Adolescent | 11 | 2020 | 18761 | 0.130 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2016 | 79 | 0.130 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2015 | 9 | 0.130 |
Why?
|
| Biopsy | 3 | 2022 | 1238 | 0.130 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 145 | 0.130 |
Why?
|
| Lung Diseases | 2 | 2016 | 378 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 660 | 0.120 |
Why?
|
| Interferon-gamma | 5 | 2012 | 506 | 0.120 |
Why?
|
| Cytokines | 2 | 2000 | 1272 | 0.120 |
Why?
|
| Electrocoagulation | 1 | 2015 | 37 | 0.120 |
Why?
|
| Cyclic AMP | 2 | 2009 | 249 | 0.120 |
Why?
|
| Urinary Fistula | 1 | 2015 | 19 | 0.120 |
Why?
|
| Pediatrics | 1 | 2024 | 1134 | 0.120 |
Why?
|
| Urethra | 1 | 2015 | 81 | 0.120 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2014 | 1 | 0.120 |
Why?
|
| Drainage | 1 | 2016 | 250 | 0.120 |
Why?
|
| Young Adult | 7 | 2020 | 8645 | 0.120 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 1 | 2014 | 9 | 0.120 |
Why?
|
| Risk Assessment | 5 | 2019 | 3203 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 590 | 0.120 |
Why?
|
| Hospital Mortality | 2 | 2017 | 976 | 0.120 |
Why?
|
| Adult | 10 | 2020 | 28389 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 201 | 0.110 |
Why?
|
| Gestational Age | 4 | 2020 | 1086 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 372 | 0.110 |
Why?
|
| Patient Selection | 1 | 2017 | 645 | 0.110 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 757 | 0.110 |
Why?
|
| Hemoglobins | 1 | 2014 | 298 | 0.110 |
Why?
|
| Alleles | 2 | 2014 | 1587 | 0.110 |
Why?
|
| Fetoscopy | 1 | 2017 | 425 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 2055 | 0.110 |
Why?
|
| Complement C7 | 1 | 2012 | 2 | 0.110 |
Why?
|
| Species Specificity | 3 | 2014 | 542 | 0.110 |
Why?
|
| Liver Transplantation | 2 | 2018 | 1030 | 0.100 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 429 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2017 | 581 | 0.100 |
Why?
|
| Treatment Outcome | 7 | 2018 | 11690 | 0.100 |
Why?
|
| Prenatal Diagnosis | 4 | 2018 | 574 | 0.100 |
Why?
|
| Laser Therapy | 1 | 2015 | 244 | 0.100 |
Why?
|
| Survival Rate | 2 | 2008 | 1981 | 0.100 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 230 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2015 | 219 | 0.100 |
Why?
|
| CD40 Ligand | 2 | 2002 | 64 | 0.100 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 3855 | 0.100 |
Why?
|
| Fibrosis | 1 | 2013 | 422 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 491 | 0.100 |
Why?
|
| Epigenomics | 1 | 2012 | 161 | 0.100 |
Why?
|
| Databases as Topic | 1 | 2011 | 68 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 943 | 0.090 |
Why?
|
| Virulence Factors, Bordetella | 2 | 2001 | 19 | 0.090 |
Why?
|
| Brain Injuries | 1 | 2016 | 729 | 0.090 |
Why?
|
| Population Groups | 1 | 2010 | 30 | 0.090 |
Why?
|
| Cognition | 1 | 2015 | 715 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2015 | 550 | 0.090 |
Why?
|
| Middle Aged | 7 | 2019 | 25297 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 568 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 730 | 0.090 |
Why?
|
| Hepcidins | 1 | 2009 | 20 | 0.080 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2009 | 33 | 0.080 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2012 | 248 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 974 | 0.080 |
Why?
|
| CD8 Antigens | 1 | 2009 | 44 | 0.080 |
Why?
|
| Quality of Life | 1 | 2019 | 1893 | 0.080 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 39 | 0.080 |
Why?
|
| Chemokine CCL2 | 2 | 2000 | 116 | 0.080 |
Why?
|
| Immunoassay | 1 | 2009 | 126 | 0.080 |
Why?
|
| Calcium | 3 | 2020 | 1089 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 240 | 0.080 |
Why?
|
| Amniotic Fluid | 2 | 2020 | 147 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2008 | 3 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 1749 | 0.080 |
Why?
|
| Macrophages | 1 | 2012 | 613 | 0.080 |
Why?
|
| Calcium Signaling | 2 | 2020 | 236 | 0.080 |
Why?
|
| Oligohydramnios | 2 | 2019 | 42 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 321 | 0.080 |
Why?
|
| Mediastinitis | 1 | 2008 | 13 | 0.080 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 218 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2021 | 5858 | 0.080 |
Why?
|
| Cryptococcosis | 1 | 2008 | 42 | 0.070 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2012 | 455 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 1 | 2007 | 66 | 0.070 |
Why?
|
| Genotype | 1 | 2013 | 2530 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2007 | 177 | 0.070 |
Why?
|
| United States | 4 | 2024 | 10347 | 0.070 |
Why?
|
| Base Sequence | 2 | 2014 | 3104 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 2780 | 0.070 |
Why?
|
| Shock, Septic | 1 | 2007 | 148 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 415 | 0.070 |
Why?
|
| Pedigree | 2 | 2022 | 1572 | 0.070 |
Why?
|
| Peptides | 1 | 2009 | 798 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2010 | 1143 | 0.060 |
Why?
|
| Linear Models | 2 | 2018 | 654 | 0.060 |
Why?
|
| Expressed Sequence Tags | 1 | 2004 | 78 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2005 | 333 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 804 | 0.060 |
Why?
|
| North America | 1 | 2005 | 229 | 0.060 |
Why?
|
| Nephrologists | 1 | 2024 | 13 | 0.060 |
Why?
|
| Complement Activation | 1 | 2004 | 54 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1389 | 0.060 |
Why?
|
| Prevalence | 1 | 2011 | 2352 | 0.060 |
Why?
|
| Self Report | 2 | 2019 | 485 | 0.060 |
Why?
|
| Reference Values | 1 | 2005 | 694 | 0.060 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2004 | 41 | 0.060 |
Why?
|
| Cell Division | 3 | 2003 | 796 | 0.060 |
Why?
|
| Apoptosis | 2 | 2008 | 1788 | 0.060 |
Why?
|
| Urothelium | 1 | 2004 | 60 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 473 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 2668 | 0.060 |
Why?
|
| Acute Disease | 3 | 2007 | 1086 | 0.060 |
Why?
|
| Bacteremia | 1 | 2007 | 406 | 0.060 |
Why?
|
| Aged | 4 | 2019 | 18432 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2024 | 194 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2015 | 2871 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1249 | 0.050 |
Why?
|
| Homozygote | 2 | 2019 | 535 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2005 | 700 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 1693 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 672 | 0.050 |
Why?
|
| Immune Sera | 1 | 2003 | 94 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 2476 | 0.050 |
Why?
|
| Leishmania tropica | 1 | 2002 | 1 | 0.050 |
Why?
|
| Leishmania major | 1 | 2002 | 24 | 0.050 |
Why?
|
| Collagen Type IV | 1 | 2022 | 20 | 0.050 |
Why?
|
| Interleukin-10 | 2 | 2002 | 171 | 0.050 |
Why?
|
| CD40 Antigens | 1 | 2002 | 25 | 0.050 |
Why?
|
| Leishmania donovani | 1 | 2002 | 20 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 390 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2004 | 897 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 1586 | 0.050 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2001 | 12 | 0.050 |
Why?
|
| Autoantigens | 1 | 2022 | 132 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1923 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2001 | 20 | 0.050 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2001 | 5 | 0.050 |
Why?
|
| Pertussis Toxin | 1 | 2001 | 24 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2022 | 169 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 999 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2001 | 68 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2001 | 140 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2001 | 2538 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2001 | 119 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2008 | 1666 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1998 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 6095 | 0.040 |
Why?
|
| Chemokine CCL8 | 1 | 2000 | 2 | 0.040 |
Why?
|
| Chemokine CCL7 | 1 | 2000 | 7 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 664 | 0.040 |
Why?
|
| Rats, Transgenic | 1 | 2020 | 16 | 0.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2020 | 21 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2019 | 15 | 0.040 |
Why?
|
| NFATC Transcription Factors | 1 | 2020 | 41 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 4194 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2014 | 706 | 0.040 |
Why?
|
| Sex Factors | 2 | 2018 | 1220 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2019 | 67 | 0.040 |
Why?
|
| Serum Albumin | 1 | 1999 | 114 | 0.040 |
Why?
|
| RNA Splice Sites | 1 | 2019 | 87 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2020 | 114 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2020 | 159 | 0.040 |
Why?
|
| Receptors, Interleukin-12 | 1 | 1999 | 9 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2019 | 156 | 0.040 |
Why?
|
| CD3 Complex | 1 | 1999 | 85 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2020 | 171 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 214 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 1999 | 80 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 42 | 0.040 |
Why?
|
| Amino Acids | 1 | 2021 | 661 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 82 | 0.040 |
Why?
|
| Th1 Cells | 1 | 1999 | 147 | 0.040 |
Why?
|
| Th2 Cells | 1 | 1999 | 181 | 0.040 |
Why?
|
| Rehabilitation | 1 | 2018 | 28 | 0.040 |
Why?
|
| Hemofiltration | 1 | 1998 | 13 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1998 | 463 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2018 | 45 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 1999 | 287 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2017 | 32 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2020 | 748 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 341 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 295 | 0.040 |
Why?
|
| Exons | 1 | 2019 | 793 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 2016 | 32 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 227 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 30 | 0.030 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 27 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2017 | 167 | 0.030 |
Why?
|
| Age Factors | 2 | 2018 | 2759 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2018 | 129 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2016 | 173 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 587 | 0.030 |
Why?
|
| Chlorides | 1 | 2016 | 103 | 0.030 |
Why?
|
| Brain Edema | 1 | 2016 | 70 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 81 | 0.030 |
Why?
|
| Antibodies | 1 | 2018 | 379 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 127 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 1806 | 0.030 |
Why?
|
| Arthritis | 1 | 2016 | 80 | 0.030 |
Why?
|
| Sodium | 1 | 2016 | 289 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 1284 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 262 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1264 | 0.030 |
Why?
|
| France | 1 | 2015 | 67 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1674 | 0.030 |
Why?
|
| Brazil | 1 | 2015 | 112 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1240 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 932 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 4966 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2014 | 285 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2020 | 989 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 966 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 369 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1473 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 549 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 651 | 0.030 |
Why?
|
| International Cooperation | 1 | 2013 | 158 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 512 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 215 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2007 | 814 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 810 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 890 | 0.020 |
Why?
|
| Anemia | 1 | 2014 | 337 | 0.020 |
Why?
|
| Germany | 1 | 2010 | 85 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 78 | 0.020 |
Why?
|
| Taxoids | 1 | 2010 | 67 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1281 | 0.020 |
Why?
|
| Microvessels | 1 | 2010 | 56 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2009 | 14 | 0.020 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2009 | 15 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 1392 | 0.020 |
Why?
|
| Hospitalization | 1 | 2018 | 1717 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2009 | 20 | 0.020 |
Why?
|
| Toxoplasmosis | 1 | 2009 | 20 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 864 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 370 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 285 | 0.020 |
Why?
|
| Rats, Inbred WKY | 1 | 2008 | 54 | 0.020 |
Why?
|
| Cryptococcus neoformans | 1 | 2008 | 20 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2008 | 15 | 0.020 |
Why?
|
| Antigens, Fungal | 1 | 2008 | 34 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 591 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3208 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 2007 | 17 | 0.020 |
Why?
|
| Animal Feed | 1 | 2008 | 76 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 328 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2013 | 504 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 207 | 0.020 |
Why?
|
| Macrophages, Peritoneal | 1 | 2007 | 37 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 128 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1231 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 111 | 0.020 |
Why?
|
| Mast Cells | 1 | 2007 | 76 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 442 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 2008 | 144 | 0.020 |
Why?
|
| Depression | 1 | 2015 | 1196 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 397 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 1225 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 295 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3402 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2008 | 257 | 0.020 |
Why?
|
| Family Practice | 1 | 2005 | 89 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2007 | 370 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2005 | 105 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2008 | 641 | 0.010 |
Why?
|
| Mice, Congenic | 1 | 2003 | 18 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2003 | 129 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2003 | 100 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 787 | 0.010 |
Why?
|
| Endotoxins | 1 | 2003 | 51 | 0.010 |
Why?
|
| Life Style | 1 | 2005 | 390 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2003 | 122 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 204 | 0.010 |
Why?
|
| Sheep | 1 | 2003 | 208 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 317 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2003 | 169 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 426 | 0.010 |
Why?
|
| Weight Loss | 1 | 2005 | 440 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2003 | 571 | 0.010 |
Why?
|
| Kidney Tubules, Distal | 1 | 2000 | 17 | 0.010 |
Why?
|
| U937 Cells | 1 | 2000 | 26 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 108 | 0.010 |
Why?
|
| Growth Substances | 1 | 2000 | 114 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2000 | 138 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2000 | 138 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 460 | 0.010 |
Why?
|
| Exercise | 1 | 2005 | 785 | 0.010 |
Why?
|
| Ureter | 1 | 2000 | 93 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 792 | 0.010 |
Why?
|
| Diet | 1 | 2005 | 1097 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2768 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 1292 | 0.010 |
Why?
|